Guggenheim cuts Jade Biosciences stock price target on model changes
Guggenheim reduced its price target for Jade Biosciences (JBIO) to $41 from $47, citing model adjustments. The stock trades at $16.14, below the analyst consensus range of $40-$77. The company expects to start a Phase 3 trial for JADE101 this quarter and report interim Phase 2 data in 2027. Other analysts maintain Buy ratings with higher targets, highlighting the company's clinical progress and financial health.
